

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-23(Cancelled)

Claim 24 (Previously Presented): A method for inhibiting an anti-HLA alloimmune antibody response in a patient comprising the step of administering a therapeutically effective amount of a soluble 18KDa recombinant human CD40L consisting of amino acids 108 to 261 set forth in SEQ ID NO:1, containing the active binding site of CD40 and capable of binding thereto.

Claim 25 (withdrawn)

Claim 26 (withdrawn)

Claim 27 (Cancelled)

Claim 28 (Cancelled)

Claim 29 (Cancelled)

Claim 30 (Currently Amended): A method for inhibiting an anti-HLA alloimmune antibody response for treating ~~or preventing~~ a disease selected from the group consisting of systemic lupus erythematosus (SLE), Sjörger's syndrome, scleroderma myositis, Raynaud's syndrome, type 1 diabetes, arthritis and rheumatoid arthritis, inflammatory bowel disease, uveitis, myasthenia gravis, multiple sclerosis, idiopathic thrombocytopenia purpura and graft vs host

Appln. No. 09/579,548
Amendment dated April 21, 2005
Reply to Office Action of January 26, 2005

disease as well as allergies which are dependent on T cells, said method comprising the step of administering a therapeutically effective amount of a soluble 18KDa recombinant human CD40L consisting of amino acids 108 to 261 of sequence set forth in SEQ ID NO:1 containing the active binding site of CD40 and capable of binding thereto.

Claims 31-33 (Cancelled)

Claim 34 (previously presented) The method of claim 30 wherein said disease is graft vs host disease.